| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
RxSight (NASDAQ:RXST) raises FY2025 sales outlook from $120.000 million-$130.000 million to $125.000 million-$130.000 million v...
RxSight (NASDAQ:RXST) reported quarterly losses of $(0.04) per share which beat the analyst consensus estimate of $(0.38) by 89...
UBS analyst Danielle Antalffy maintains RxSight (NASDAQ:RXST) with a Neutral and lowers the price target from $16 to $8.
Stifel analyst Tom Stephan maintains RxSight (NASDAQ:RXST) with a Hold and lowers the price target from $9 to $8.
Needham analyst David Saxon maintains RxSight (NASDAQ:RXST) with a Buy and lowers the price target from $22 to $11.
RxSight (NASDAQ:RXST) affirms FY2025 sales outlook from $120.00 million-$130.00 million to $120.00 million-$130.00 million vs $...
RxSight (NASDAQ:RXST) reported quarterly losses of $(0.08) per share which beat the analyst consensus estimate of $(0.17) by 52...